Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
The DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates - soluble oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid beta-protein oligomers adversely affect synaptic structure and plasticity. Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation suggests that oligodendrocytes could potentially generate a relatively higher proportion of longer Aβ species, which are more prone to aggregation [28]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“The increased Aβ 42:40 ratio in oligodendrocytes could contribute to the high proportion of soluble aggregates [28,42,43]”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“and, consequently, could be more pathogenic than shorter Aβ species”
From Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer’s disease (2024) · cites this paper as [28]
In the citing paper
“However, recent in vivo studies have shown that soluble Aβ oligomers are more neurotoxic than amyloid plaques and most likely responsible for synaptic dysfunction and memory loss in AD.7–11”
From The effect of Cu2+ and Zn2+ on the Aβ42 peptide aggregation and cellular toxicity (2013) · cites this paper as [8]
In the citing paper
“Dysregulation of A peptide metabolism is hypothesized to initiate pathogenic cascades that lead to Alzheimer's disease (AD) (Haass and Selkoe, 2007).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Haass and Selkoe, 2007
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Self-citationSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“These and other findings led to the formal proposal of a hypothesis of disease in which excessive Aβ accumulation and deposition could trigger a complex downstream cascade that resulted in the symptoms of A”
ResultRosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062 · cited 1×
“In a similar manner, breakthrough discoveries of causative genes allowed the subsequent identification of aggregation-prone proteins in disorders such as amyotrophic lateral sclerosis (ALS”
ResultUbiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 1×
“More recently, TDP43 was found to be deposited in tau- and synuclein-negative inclusions in a disorder designated as frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U) as well as in AL”
BackgroundGlenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“Shortly thereafter, a distinct APP missense mutation was found in a family with early-onset A”
Background
Cited by
Items 201–300 of 1,119
Proteotoxicity and Cardiac Dysfunction — Alzheimer's Disease of the Heart?
Willis, M. S., & Patterson, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1106180 · Cited by 284
Zempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E., & Mandelkow, E. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.207 · Cited by 283
“In familial AD, genetic evidence points to a master role of A b aggregation, leading to downstream events including Tau hyperphosphorylation and aggregation (Haass and Selkoe, 2007; Karran et al , 2011).”
Bosco, D., Fava, A., Plastino, M., Montalcini, T., & Pujia, A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01318.x · Cited by 283
“Although monomeric A is not neurotoxic, the A oligomers exhibits a marked toxicity [128].”
BackgroundNeuroprotective and Anti-Aging Potentials of Essential Oils from Aromatic and Medicinal Plants
Ayaz, M., Sadiq, A., Junaid, M., Ullah, F., Subhan, F., & Ahmed, J. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00168 · Cited by 281
“Among the pathological aspects of AD, the formation of cerebral plaques loaded with β-amyloid peptide (Aβ), congophilic (amyloid) angiopathy, dystrophic neuritis, appearance of NFTs in temporal lobe, loss of cholinergic neurons and white matter are important hallmarks (Haass and Selkoe, 2007).”
BackgroundTsigelny, I. F., Crews, L., Desplats, P., Shaked, G. M., Sharikov, Y., Mizuno, H., Spencer, B., Rockenstein, E., Trejo, M., Platoshyn, O., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003135 · Cited by 281
“in the size and conformation of the toxic oligomers [6,8].”
BackgroundRetractedBolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzig, M. C., Radde, R., Staufenbiel, M., Lewis, J., Hutton, M., Tolnay, M., & Jucker, M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070403 · Cited by 281
Parallel findings in age-related macular degeneration and Alzheimer’s disease
Ohno-Matsui, K. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.02.004 · Cited by 280
“1) (Haass and Selkoe, 2007).”
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
Farlow, M., Arnold, S. E., van Dyck, C. H., Aisen, P. S., Snider, B. J., Porsteinsson, A. P., Friedrich, S., Dean, R. A., Gonzales, C., Sethuraman, G., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.09.224 · Cited by 280
“Deposited amyloid plaques or oligomeric species of Ab [5] have been suggested as potential targets for disease-modifying treatments for AD [6].”
BackgroundAllaman, I., Gavillet, M., Bélanger, M., Laroche, T., Viertl, D., Lashuel, H. A., & Magistretti, P. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5098-09.2010 · Cited by 278
“A peptides are produced by the proteolytic cleavage of the transmembrane amyloid precursor protein (APP) by - and -secretases (Haass and Selkoe, 2007), producing mainly A 1-40 and A 1-42, peptides of 40 and 42 residues in length, respectively.”
BackgroundInfluentialA zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation
Paquet, D., Bhat, R., Sydow, A., Mandelkow, E.-M., Berg, S., Hellberg, S., Fälting, J., Distel, M., Köster, R. W., Schmid, B., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37537 · Cited by 278
Self-citationResveratrol for Alzheimer's disease
Sawda, C., Moussa, C., & Turner, R. S. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13431 · Cited by 276
Zhang, Z., Song, M., Liu, X., Su Kang, S., Duong, D. M., Seyfried, N. T., Cao, X., Cheng, L., Sun, Y. E., Ping Yu, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9762 · Cited by 277
Amyloid β-protein oligomers and Alzheimer’s disease
Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276
“Similarly, acute effects of exogenous oligomeric assemblies on memory and hippocampal LTP in rodents have been reported in vivo (reviewed in [54]).”
BackgroundAutophagic degradation of tau in primary neurons and its enhancement by trehalose
Krüger, U., Wang, Y., Kumar, S., & Mandelkow, E.-M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.009 · Cited by 297
“Intracellular tau aggregates and extracellular -amyloid (A ) deposits are 2 pathologic hallmarks found in Alzheimer’s disease (AD) (Ballatore et al., 2007; Haass and Selkoe, 2007).”
BackgroundClearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L., Daley, D., Black, K. L., & Koronyo-Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 275
The ER stress factor XBP1s prevents amyloid-β neurotoxicity
Casas-Tinto, S., Zhang, Y., Sanchez-Garcia, J., Gomez-Velazquez, M., Rincon-Limas, D. E., & Fernandez-Funez, P. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr100 · Cited by 275
Recent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“…and protofibrillar derivatives of misfolded proteins may play a pathogenic role (Catalano et al. 2006; Csizmók and Tompa 2009; Gong et al. 2003; Haass and Selkoe 2007; Hu et al. 2008; Irvine et al. 2008; Israeli and Sharon 2009; Kokubo et al. 2005; Lee et al. 2006; Resende et al. 2008; Rowan…”
BackgroundShaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases
Fão, L., Mota, S. I., & Rego, A. C. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100942 · Cited by 270
Neuronal hyperactivity--A key defect in Alzheimer’s disease?
Busche, M. A., & Konnerth, A. (2015) · BioEssays · doi:10.1002/bies.201500004 · Cited by 266
“Substantial human genetic [6, 7], biomarker [4, 8, 9], histopathological [10, 11], and animal model [12–15] data indicate that the 39–42 amino-acid peptide amyloid-ß plays a prime role in the pathogenesis of AD, which is viewed as a cascade of events initiating from the excessive accumulation and deposition of amyloid…”
BackgroundWidespread aggregation and neurodegenerative diseases are associated with supersaturated proteins
Ciryam, P., Tartaglia, G. G., Morimoto, R. I., Dobson, C. M., & Vendruscolo, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.043 · Cited by 270
“Supersaturation Scores RationalizeWidespread Protein Aggregation under Stress Because a wide range of proteins is known to form fibrillar assemblies within the cell (Chapman et al., 2006; Chiti and Dobson, 2006; David et al., 2010; Fowler et al., 2007; Gidalevitz et al., 2006; Haass and Selkoe, 2007; Hartl et al., 201…”
Scotter, E. L., Vance, C., Nishimura, A. L., Lee, Y.-B., Chen, H.-J., Urwin, H., Sardone, V., Mitchell, J. C., Rogelj, B., Rubinsztein, D. C., et al. (2014) · Journal of Cell Science · doi:10.1242/jcs.140087 · Cited by 268
“The emerging consensus is that macroaggregates might be a ‘sink’ for the true toxic species, which are predominantly lowerorder oligomers with greater mobility and surface area, and thus have enhanced potential for aberrant interactions (Caughey and Lansbury, 2003; Haass and Selkoe, 2007).”
BackgroundDiagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease
Patterson, C., Feightner, J. W., Garcia, A., Hsiung, G.-Y. R., MacKnight, C., & Sadovnick, A. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.070796 · Cited by 268
“Simultaneously, the oligomers may aggregate into insoluble β-sheet amyloid fibrils, which can trigger a local inflammatory response.(22) Over time, the subsequent oxidative stress and bio-”
BackgroundReviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review
Minati, L., Edginton, T., Grazia Bruzzone, M., & Giaccone, G. (2009) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317508328602 · Cited by 268
“Furthermore, in recent years evidence has accumulated pointing to a significant neurotoxicity of Abeta oligomers, which have much larger surface-to-volume ratio and diffusivity.(37) Neurofibrillary tangles, the other neuropathological hallmark of AD, are principally composed of abnormally phosphorylated tau protein, a…”
BackgroundYoo, S. I., Yang, M., Brender, J. R., Subramanian, V., Sun, K., Joo, N. E., Jeong, S., Ramamoorthy, A., & Kotov, N. A. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201007824 · Cited by 269
AA Amyloidosis: Pathogenesis and Targeted Therapy
Westermark, G. T., Fändrich, M., & Westermark, P. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163913 · Cited by 264
Choi, J.-S., Braymer, J. J., Nanga, R. P. R., Ramamoorthy, A., & Lim, M. H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006091107 · Cited by 264
“Left: (1) [Aβþ Cu2þ]; (2) [1þ L2-a]; (3) [1þ L2-b]; (4) [1þ CQ]; (5) [1þ phen]; (6) [1þ EDTA].”
BackgroundMethodInfluentialSite-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice
Ittner, A., Chua, S. W., Bertz, J., Volkerling, A., van der Hoven, J., Gladbach, A., Przybyla, M., Bi, M., van Hummel, A., Stevens, C. H., et al. (2016) · Science · doi:10.1126/science.aah6205 · Cited by 263
Gao, N., Sun, H., Dong, K., Ren, J., Duan, T., Xu, C., & Qu, X. (2014) · Nature Communications · doi:10.1038/ncomms4422 · Cited by 263
Ma, T., Hoeffer, C. A., Capetillo-Zarate, E., Yu, F., Wong, H., Lin, M. T., Tampellini, D., Klann, E., Blitzer, R. D., & Gouras, G. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012845 · Cited by 262
“term potentiation (LTP) and causing learning and memory deficits [1,2].”
BackgroundPullulan and pullulan derivatives as promising biomolecules for drug and gene targeting
Singh, R. S., Kaur, N., & Kennedy, J. F. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2015.01.032 · Cited by 262
Efficient Inhibition of the Alzheimer's Disease β-Secretase by Membrane Targeting
Rajendran, L., Schneider, A., Schlechtingen, G., Weidlich, S., Ries, J., Braxmeier, T., Schwille, P., Schulz, J. B., Schroeder, C., Simons, M., et al. (2008) · Science · doi:10.1126/science.1156609 · Cited by 262
SRF and myocardin regulate LRP-mediated amyloid-β clearance in brain vascular cells
Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., Singh, I., Streb, J. W., Guo, H., Rubio, A., Van Nostrand, W., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1819 · Cited by 261
γ-Secretase Heterogeneity in the Aph1 Subunit: Relevance for Alzheimer’s Disease
Serneels, L., Van Biervliet, J., Craessaerts, K., Dejaegere, T., Horré, K., Van Houtvin, T., Esselmann, H., Paul, S., Schäfer, M. K., Berezovska, O., et al. (2009) · Science · doi:10.1126/science.1171176 · Cited by 260
APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease
Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., Kim, J., Eimer, W. A., Estus, S., Rebeck, G. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407957 · Cited by 268
“By IHC, intraneuronal A (12–14) and perhaps specific plaque morphologies (15, 16) are thought to contribute to A pathology, although amyloid plaque burden per semay not be neurotoxic (17).”
BackgroundMetal-associated amyloid-β species in Alzheimer's disease
Pithadia, A. S., & Lim, M. H. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.01.016 · Cited by 259
Fjorback, A. W., Seaman, M., Gustafsen, C., Mehmedbasic, A., Gokool, S., Wu, C., Militz, D., Schmidt, V., Madsen, P., Nyengaard, J. R., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2272-11.2012 · Cited by 253
“Elevated production of the amyloid (A ) peptide is widely accepted as a neurotoxic event in Alzheimer’s disease (AD) (Haass and Selkoe, 2007).”
BackgroundSoluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic
Takahashi, T., Kikuchi, S., Katada, S., Nagai, Y., Nishizawa, M., & Onodera, O. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm311 · Cited by 258
“In many neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, soluble oligomers of causative proteins have been proposed to be the cytotoxic structure (23,43).”
BackgroundMagdesian, M. H., Carvalho, M. M. V. F., Mendes, F. A., Saraiva, L. M., Juliano, M. A., Juliano, L., Garcia-Abreu, J., & Ferreira, S. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707108200 · Cited by 221
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
Cummings, J. L., Cohen, S., van Dyck, C. H., Brody, M., Curtis, C., Cho, W., Ward, M., Friesenhahn, M., Rabe, C., Brunstein, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005550 · Cited by 252
Ono, K., Li, L., Takamura, Y., Yoshiike, Y., Zhu, L., Han, F., Mao, X., Ikeda, T., Takasaki, J.-I., Nishijo, H., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.325456 · Cited by 251
Habchi, J., Chia, S., Galvagnion, C., Michaels, T. C. T., Bellaiche, M. M. J., Ruggeri, F. S., Sanguanini, M., Idini, I., Kumita, J. R., Sparr, E., et al. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0031-x · Cited by 249
Matter over mind: Liquid phase separation and neurodegeneration
Elbaum-Garfinkle, S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.rev118.001188 · Cited by 249
Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib
Domínguez, J. M., Fuertes, A., Orozco, L., del Monte-Millán, M., Delgado, E., & Medina, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.306472 · Cited by 246
Lin, Y.-C., & Koleske, A. J. (2010) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153204 · Cited by 248
“ADDL levels correlate better than APs with the cognitive impairment in AD patients, and injection of patient-derived ADDLs into animals can induce acute memory loss, suggesting a direct link between ADDLs and AD symptomology (Haass & Selkoe 2007, Shankar et al. 2008).”
Alzheimer’s-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions
Szaruga, M., Munteanu, B., Lismont, S., Veugelen, S., Horré, K., Mercken, M., Saido, T. C., Ryan, N. S., De Vos, T., Savvides, S. N., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.004 · Cited by 248
Calcium and Mitochondrial Reactive Oxygen Species Generation: How to Read the Facts
Adam-Vizi, V., & Starkov, A. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100465 · Cited by 246
“This is remarkable as soluble oligomers are thought to mostly contribute to the AD pathological changes in the brain [164].”
BackgroundAmyloid-β as a Modulator of Synaptic Plasticity
Parihar, M. S., & Brewer, G. J. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101020 · Cited by 247
“A β promotes glutamatergic excito-toxicity and potently disrupts glutamatergic synapses and plasticity providing an explanationforthe cognitive deficits in AD [217].”
Ghosal, K., Vogt, D. L., Liang, M., Shen, Y., Lamb, B. T., & Pimplikar, S. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907652106 · Cited by 245
“Recently, soluble aggregates of A peptides have been proposed to be the toxic agent (13).”
BackgroundNative ion mobility-mass spectrometry and related methods in structural biology
Konijnenberg, A., Butterer, A., & Sobott, F. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.11.013 · Cited by 245
“Especially with the suggestion that these small aggromeric species could lie at the basis of the toxicity of amyloid diseases rather than the insoluble fibrils, IM-MS investigations grow ever more important [77–79].”
BackgroundAmyloid β-Protein Monomer Folding: Free-Energy Surfaces Reveal Alloform-Specific Differences
Yang, M., & Teplow, D. B. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.039 · Cited by 247
Resenberger, U. K., Harmeier, A., Woerner, A. C., Goodman, J. L., Müller, V., Krishnan, R., Vabulas, R. M., Kretzschmar, H. A., Lindquist, S., Hartl, F. U., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.86 · Cited by 248
“However, there is an ongoing debate about the nature of the harmful proteinaceous species and how toxic conformers selectively damage neuronal popula- tions (reviewed in Haass and Selkoe, 2007; Winklhofer et al, 2008; Ilieva et al, 2009).”
BackgroundGoozee, K. G., Shah, T. M., Sohrabi, H. R., Rainey-Smith, S. R., Brown, B., Verdile, G., & Martins, R. N. (2016) · British Journal of Nutrition · doi:10.1017/s0007114515004687 · Cited by 244
“Aβ accumulation is reported to be associated with impaired synaptic function((46)), reduced neurite outgrowth((47)), cerebral atrophy((48,49)) and reduced cognitive performance, particularly when deposited within the temporal region((50)).”
Insights from molecular dynamics simulations for computational protein design
Childers, M. C., & Daggett, V. (2017) · Molecular Systems Design & Engineering · doi:10.1039/c6me00083e · Cited by 240
Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease
Crouch, P. J., Harding, S.-M. E., White, A. R., Camakaris, J., Bush, A. I., & Masters, C. L. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.07.013 · Cited by 244
Zhao, Y., Calon, F., Julien, C., Winkler, J. W., Petasis, N. A., Lukiw, W. J., & Bazan, N. G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015816 · Cited by 243
Neurosteroids as regulators of neuroinflammation
Yilmaz, C., Karali, K., Fodelianaki, G., Gravanis, A., Chavakis, T., Charalampopoulos, I., & Alexaki, V. I. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2019.100788 · Cited by 213
“Pathological hallmarks in the brain of AD patients are formation of amyloid plaques composed by amyloid β1–42 and β1–40 peptides, which are derived from amyloid precursor protein (APP) through cleavage by β and γ secretases, and intraneural neurofibrillary tangles (NFTs), composed by hyper-phosphorylated microtubule-b…”
Ge, X., Guo, M., Hu, T., Li, W., Huang, S., Yin, Z., Li, Y., Chen, F., Zhu, L., Kang, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.017 · Cited by 242
“In addition, Ab is derived from its precursor protein, APP, and aggregates to form soluble oligomers Ab1–40 and Ab1–42, which are toxic to nerve cells.(36) Therefore, the expression levels of APP and Ab in neurons, and those of Ab1–40 and Ab1–42 in the culture medium, were assessed.”
BackgroundMurakami, K., Murata, N., Noda, Y., Tahara, S., Kaneko, T., Kinoshita, N., Hatsuta, H., Murayama, S., Barnham, K. J., Irie, K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.279208 · Cited by 241
Sleep architecture and the risk of incident dementia in the community
Pase, M. P., Himali, J. J., Grima, N. A., Beiser, A. S., Satizabal, C. L., Aparicio, H. J., Thomas, R. J., Gottlieb, D. J., Auerbach, S. H., & Seshadri, S. (2017) · Neurology · doi:10.1212/wnl.0000000000004373 · Cited by 241
“Body mass index, kg/m2 28 (5) 28 (5) 27 (4)”
InfluentialIn Vitro and In Vivo Neurotoxicity of Prion Protein Oligomers
Simoneau, S., Rezaei, H., Salès, N., Kaiser-Schulz, G., Lefebvre-Roque, M., Vidal, C., Fournier, J.-G., Comte, J., Wopfner, F., Grosclaude, J., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030125 · Cited by 240
“is related to soluble oligomeric species rather than to high molecular weight protein assemblies [21,24].”
BackgroundDecoding DNA, RNA and peptides with quantum tunnelling
Di Ventra, M., & Taniguchi, M. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.320 · Cited by 242
MicroRNA-101 Regulates Amyloid Precursor Protein Expression in Hippocampal Neurons
Vilardo, E., Barbato, C., Ciotti, M., Cogoni, C., & Ruberti, F. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.112664 · Cited by 238
Soluble Aβ Seeds Are Potent Inducers of Cerebral β-Amyloid Deposition
Langer, F., Eisele, Y. S., Fritschi, S. K., Staufenbiel, M., Walker, L. C., & Jucker, M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3088-11.2011 · Cited by 237
“In AD research, a variety of pathogenic A species have been described, ranging from A dimers to larger oligomers, protofibrils, and fibrils (for review, see Haass and Selkoe, 2007; Glabe, 2008).”
Drosophila melanogaster in the Study of Human Neurodegeneration
Hirth, F. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791556104 · Cited by 235
Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus
Ashraf, G., Greig, N., Khan, T., Hassan, I., Tabrez, S., Shakil, S., Sheikh, I., Zaidi, S., Akram, M., Jabir, N., et al. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917095514 · Cited by 236
“Thereafter, a γsecretase complex, which comprises PS1 or PS2, nicastrin, anterior pharynx-defective-1 (APH-1), and presenilin enhancer-2 (PEN-2), cleaves the remaining fragment of membrane bound APP at the C-terminus resulting in the generation of monomeric Aβ peptides of varying lengths [25, 51, 56].”
BackgroundInfluentialCurrent and Emerging Drug Treatment Options for Alzheimerʼs Disease: A Systematic Review
Herrmann, N., Chau, S. A., Kircanski, I., & Lanctôt, K. L. (2011) · Drugs · doi:10.2165/11595870-000000000-00000 · Cited by 237
“In recent years, soluble oligomers of Ab, rather than large assemblies of fibrillary Abs, have been strongly linked with neuro- and synaptotoxicity,([187-189]) leading to AD pathology.”
BackgroundThe future of Alzheimer's disease: The next 10 years
Hampel, H., Prvulovic, D., Teipel, S., Jessen, F., Luckhaus, C., Frölich, L., Riepe, M. W., Dodel, R., Leyhe, T., Bertram, L., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.008 · Cited by 235
JNK3 Perpetuates Metabolic Stress Induced by Aβ Peptides
Yoon, S. O., Park, D. J., Ryu, J. C., Ozer, H. G., Tep, C., Shin, Y. J., Lim, T. H., Pastorino, L., Kunwar, A. J., Walton, J. C., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.06.024 · Cited by 230
“Recent findings suggest that soluble oligomeric are the pathogenic forms, eliciting neurotoxic effects that culminate in synaptic dysfunction and neuronal loss (Haass and Selkoe, 2007).”
BackgroundMaiti, P., & Dunbar, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061637 · Cited by 233
Analyzing dendritic spine pathology in Alzheimer’s disease: Problems and opportunities
Dorostkar, M. M., Zou, C., Blazquez-Llorca, L., & Herms, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1449-5 · Cited by 235
“The following variants are commonly distinguished [73, 77]: Protofibrils, which are betasheet containing intermediates of synthetic amyloid beta fibrillization; Annular assemblies and globulomers, which are both synthetic products; Amyloid beta-derived diffusible ligands, which are small, diffusible synthetic products…”
BackgroundNovel Research Horizons for Presenilins and γ-Secretases in Cell Biology and Disease
De Strooper, B., & Annaert, W. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100109-104117 · Cited by 234
Leitman, J., Ulrich Hartl, F., & Lederkremer, G. Z. (2013) · Nature Communications · doi:10.1038/ncomms3753 · Cited by 233
Deshpande, A., Kawai, H., Metherate, R., Glabe, C. G., & Busciglio, J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5980-08.2009 · Cited by 232
“…abnormal deposition of protein aggregates in the form of extracellular plaques composed of fibrillar amyloid protein (A ) and intracellular neurofibrillary tangles composed of hyperphosphorylated tau (Selkoe, 1991; Trojanowski and Lee, 2002; Goedert and Spillantini, 2006; Haass and Selkoe, 2007).”
BackgroundSato, M., Murakami, K., Uno, M., Nakagawa, Y., Katayama, S., Akagi, K.-I., Masuda, Y., Takegoshi, K., & Irie, K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.464222 · Cited by 230
Lichtenthaler, S. F., Haass, C., & Steiner, H. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07248.x · Cited by 205
Self-citationCurcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide
Mourtas, S., Canovi, M., Zona, C., Aurilia, D., Niarakis, A., La Ferla, B., Salmona, M., Nicotra, F., Gobbi, M., & Antimisiaris, S. G. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.027 · Cited by 230
Calcium signaling in Alzheimer's disease & therapies
Tong, B. C.-K., Wu, A. J., Li, M., & Cheung, K.-H. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.07.018 · Cited by 231
Insulin Resistance in Alzheimer's Disease
Ferreira, L. S. S., Fernandes, C. S., Vieira, M. N. N., & De Felice, F. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00830 · Cited by 228
“One of the most accepted hypothesis to explain AD is that pathology develops as consequence of the build up of Aβ oligomers and amyloid plaques in the brain (Hardy and Higgins, 1992; Haass and Selkoe, 2007).”
BackgroundThe Supramolecular Chemistry of β-Sheets
Cheng, P.-N., Pham, J. D., & Nowick, J. S. (2013) · Journal of the American Chemical Society · doi:10.1021/ja3088407 · Cited by 228
Rasmussen, J., Mahler, J., Beschorner, N., Kaeser, S. A., Häsler, L. M., Baumann, F., Nyström, S., Portelius, E., Blennow, K., Lashley, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713215114 · Cited by 227
“Finally, it will be important to establish the relationship between the variant molecular structure of plaque cores and the pathobiologically potent oligomeric forms of Aβ (31, 47).”
BackgroundImpaired Glutathione Synthesis in Neurodegeneration
Aoyama, K., & Nakaki, T. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141021021 · Cited by 226
“In the form of soluble oligomers, Aβ is most toxic, causing oxidative stress that leads to NFT formation and neuronal death [136,137].”
BackgroundFrom sirtuin biology to human diseases: an update
Sebastián, C., Satterstrom, F. K., Haigis, M. C., & Mostoslavsky, R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.402768 · Cited by 201
FROSCH, M. P., ANTHONY, D. C., & DE GIROLAMI, U. (2010) · Robbins and Cotran Pathologic Basis of Disease · doi:10.1016/b978-1-4377-0792-2.50033-x · Cited by 226
β‐amyloid burden is not associated with rates of brain atrophy
Josephs, K. A., Whitwell, J. L., Ahmed, Z., Shiung, M. M., Weigand, S. D., Knopman, D. S., Boeve, B. F., Parisi, J. E., Petersen, R. C., Dickson, D. W., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21223 · Cited by 225
Drachman, D. A. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.11.003 · Cited by 224
“This hypothesis proposes that excess toxic accumulation of amyloid-b (Ab) in one or more forms [3]—compact plaques, diffuse plaques, soluble oligomers [4,5], fibrils, protofibrils—is the specific cause of AD.”
BackgroundHabchi, J., Chia, S., Limbocker, R., Mannini, B., Ahn, M., Perni, M., Hansson, O., Arosio, P., Kumita, J. R., Challa, P. K., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615613114 · Cited by 223
Kurup, P., Zhang, Y., Xu, J., Venkitaramani, D. V., Haroutunian, V., Greengard, P., Nairn, A. C., & Lombroso, P. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0157-10.2010 · Cited by 224
“A hallmark of AD is the accumulation of amyloid (A ) peptide in brains, a process that has been implicated in the progression of the disease (Haass and Selkoe, 2007).”
BackgroundProtein folding stress in neurodegenerative diseases: a glimpse into the ER
Matus, S., Glimcher, L. H., & Hetz, C. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.01.003 · Cited by 226
Ali, T., & Kim, M. O. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12238 · Cited by 223
“In AD, Ab production and aggregation in the human brain has been associated with neuronal dysfunction and memory disorders [49].”
BackgroundMorel, E., Chamoun, Z., Lasiecka, Z. M., Chan, R. B., Williamson, R. L., Vetanovetz, C., Dall’Armi, C., Simoes, S., Point Du Jour, K. S., McCabe, B. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3250 · Cited by 222
Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration
Li, X., Kumar, Y., Zempel, H., Mandelkow, E., Biernat, J., & Mandelkow, E. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.376 · Cited by 223
“…and 2German Center for Neurodegenerative Diseases (DZNE) and CAESAR, Ludwig-Erhard-Allee 2, Bonn, Germany Missorting of Tau from axons to the somatodendritic compartment of neurons is a hallmark of Alzheimer’s disease, but the mechanisms underlying normal sorting and pathological failure…”
BackgroundEmerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease
Lewcock, J. W., Schlepckow, K., Di Paolo, G., Tahirovic, S., Monroe, K. M., & Haass, C. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.029 · Cited by 221
Self-citationNekooki-Machida, Y., Kurosawa, M., Nukina, N., Ito, K., Oda, T., & Tanaka, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812083106 · Cited by 220
The Aging Eye: Common Degenerative Mechanisms Between the Alzheimer's Brain and Retinal Disease
Sivak, J. M. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10827 · Cited by 220
Kumar, S., Rezaei‐Ghaleh, N., Terwel, D., Thal, D. R., Richard, M., Hoch, M., Mc Donald, J. M., Wüllner, U., Glebov, K., Heneka, M. T., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.138 · Cited by 219
“Notably, recent research also strongly supports an important role of small oligomeric forms of Ab in neurotoxicity and degeneration (Yankner, 1996; Chiti and Dobson, 2006; Haass and Selkoe, 2007; Selkoe, 2008).”
BackgroundResultSanz-Blasco, S., Valero, R. A., Rodríguez-Crespo, I., Villalobos, C., & Núñez, L. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002718 · Cited by 219
“Small assemblies (oligomers) of unmodified Ab are becoming the proximate neurotoxin in AD [13,14], but most studies used fibrils.”
BackgroundPeptide dimer structure in an Aβ(1–42) fibril visualized with cryo-EM
Schmidt, M., Rohou, A., Lasker, K., Yadav, J. K., Schiene-Fischer, C., Fändrich, M., & Grigorieff, N. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503455112 · Cited by 217
“Murakami K, et al. (2003) Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: Implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer’s disease.”
BackgroundResultInfluentialRosenman, D. J., Connors, C. R., Chen, W., Wang, C., & García, A. E. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.06.021 · Cited by 218
“predominant of these species are Aβ40 (~90% of Aβ content secreted by all cells) and Aβ42 (~10%), the latter of which is characterized by higher amyloidogenicity and toxicity [5,6].”
Three-Dimensional Study of Alzheimer’s Disease Hallmarks Using the iDISCO Clearing Method
Liebmann, T., Renier, N., Bettayeb, K., Greengard, P., Tessier-Lavigne, M., & Flajolet, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.060 · Cited by 218
de Godoy, M. A., Saraiva, L. M., de Carvalho, L. R. P., Vasconcelos-dos-Santos, A., Beiral, H. J. V., Ramos, A. B., Silva, L. R. D. P., Leal, R. B., Monteiro, V. H. S., Braga, C. V., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807180 · Cited by 214
Metadata
- Authors
- Haass, C., & Selkoe, D. J.
- Affiliations
- Adolf-Butenandt-Institut für Physiologische Chemie, Physikalische Biochemie und Zellbiologie (DE)
- Venue
- Nature Reviews Molecular Cell Biology
- Published
- 2007-02
- Volume
- 8
- Issue
- 2
- Pages
- 101-112
- ISSN
- 1471-0072 (ISSN-L)
- 1471-0080
- OpenAlex
- W1980825524
- Cited by
- 4,744
- References
- 135
- Citations by year
- 2026: 135 · 2025: 171 · 2024: 165 · 2023: 170 · 2022: 195 · 2021: 239 · 2020: 273 · 2019: 247 · 2018: 276 · 2017: 290 · 2016: 331 · 2015: 313 · 2014: 285 · 2013: 307 · 2012: 327
- FWCI
- 25.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Molecular Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, neurodegeneration, protein misfolding, protein aggregation, synaptic dysfunction, synaptic plasticity, Parkinson's disease, Huntington's disease, prion disease, neuronal dysfunction
- MeSH terms
- Alzheimer Disease, Cell Membrane, Humans, Memory Disorders, Models, Biological, Nerve Degeneration, Solubility, Synapses, Signal Transduction, Amyloid beta-Peptides, Protein Folding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.